ArticleAnnals of translational medicine2022
Preparation and identification of an anti-nicarbazin monoclonal antibody and its application in the agriculture and food industries.
Article in Annals of translational medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 citations in OpenAlex.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: As a broad-spectrum drug against chicken coccidiosis, nicarbazine is widely used. The international community has made regulations and requirements on the residue limits of nicarbazine metabolites in chicken. The research reports on the detection methods of nicarbazine residues are mainly based on large-scale instruments such as high-performance liquid chromatography (HPLC), liquid chromatography-mass spectrometry-mass spectrometry (LC/MS/MS) and so on. However, in the practical monitoring and detection application, the rapid, sensitive, efficient and accurate detection of nicarbazine residues is becoming more and more urgent. Methods: This study aimed to establish an enzyme-linked immunosorbent assay (ELISA)-based method to detect nicarbazin drug residues with high sensitivity and specificity, and wide applicability. Artificial immunogens were prepared by molecular modification synthesis. Nuclear magnetic resonance (NMR) and ultraviolet analyses were conducted to confirm that the correct product was obtained. Monoclonal antibodies were acquired by immunizing mice and preparing hybridoma cells. Results: In this study, 4,4'-dinitrocarbanilide (DNC), a metabolite of nicarbazine, was synthesized and modified to make it have immunogenicity. Fifteen healthy female mice of 6-8 weeks old were immunized in three groups. The successfully immunized mice were screened by serum titer. One mouse with the highest titer was fused and cloned three times, and four positive cell lines were obtained. Nine monoclonal antibodies were obtained from mouse ascites. The best matched antigens and antibodies were screened by an ELISA chessboard method. A detection method of nicarbazine ELISA kit was developed. Our prepared anti-nicarbazin monoclonal antibody had a half-maximal inhibitory concentration (IC Conclusions: This method, which uses a specific antibody against the nicarbazin metabolic product DNC, enables rapid quantitative detection. Our new ELISA-based method should facilitate the development of assays to monitor and detect agricultural and veterinary drug residues.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.